JP2014531584A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531584A5
JP2014531584A5 JP2014530245A JP2014530245A JP2014531584A5 JP 2014531584 A5 JP2014531584 A5 JP 2014531584A5 JP 2014530245 A JP2014530245 A JP 2014530245A JP 2014530245 A JP2014530245 A JP 2014530245A JP 2014531584 A5 JP2014531584 A5 JP 2014531584A5
Authority
JP
Japan
Prior art keywords
cells
ccr9
foxp3
amount
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014530245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531584A (ja
JP6389122B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/068146 external-priority patent/WO2013037970A1/en
Publication of JP2014531584A publication Critical patent/JP2014531584A/ja
Publication of JP2014531584A5 publication Critical patent/JP2014531584A5/ja
Application granted granted Critical
Publication of JP6389122B2 publication Critical patent/JP6389122B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014530245A 2011-09-15 2012-09-14 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 Expired - Fee Related JP6389122B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11425234 2011-09-15
EP11425234.9 2011-09-15
US201161576556P 2011-12-16 2011-12-16
US61/576,556 2011-12-16
PCT/EP2012/068146 WO2013037970A1 (en) 2011-09-15 2012-09-14 Methods for monitoring responsiveness to anti-smad7 therapy

Publications (3)

Publication Number Publication Date
JP2014531584A JP2014531584A (ja) 2014-11-27
JP2014531584A5 true JP2014531584A5 (https=) 2015-11-05
JP6389122B2 JP6389122B2 (ja) 2018-09-12

Family

ID=47882658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530245A Expired - Fee Related JP6389122B2 (ja) 2011-09-15 2012-09-14 抗ｓｍａｄ７治療に対する応答性をモニターするための方法

Country Status (11)

Country Link
US (2) US9791442B2 (https=)
EP (2) EP3165929A3 (https=)
JP (1) JP6389122B2 (https=)
KR (1) KR102099990B1 (https=)
CN (1) CN104040349B (https=)
AU (1) AU2012307336B2 (https=)
CA (1) CA2848595A1 (https=)
ES (1) ES2617200T3 (https=)
MX (1) MX350087B (https=)
RU (1) RU2678450C2 (https=)
WO (1) WO2013037970A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
US10081809B2 (en) 2012-04-18 2018-09-25 University Of Miami Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2674147C2 (ru) * 2013-03-15 2018-12-05 Ногра Фарма Лимитед Способы лечения колоректального рака
US20160139123A1 (en) * 2013-07-12 2016-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Shear Wave Imaging Method and Installation for Collecting Information on a Soft Solid
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2016059239A1 (en) * 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
US20170233736A1 (en) * 2014-10-17 2017-08-17 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
WO2017019673A2 (en) * 2015-07-27 2017-02-02 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
MX2018003699A (es) * 2015-09-30 2018-08-01 Celgene Alpine Invest Company Ii Llc Moduladores de tlr y metodos de uso.
EP3355896A2 (en) * 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
JP2019505598A (ja) 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
US11619832B2 (en) 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
CN110082538B (zh) * 2019-04-19 2021-12-03 中山大学附属第六医院 CCR9+IL-17+Treg细胞在制备用于检测NEC的试剂盒中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
RU2185627C2 (ru) * 2000-09-11 2002-07-20 Новосибирская государственная медицинская академия Способ определения чувствительности (восприимчивости) к внутривенной лазеротерапии больных ишемической болезнью сердца
PT1456380E (pt) 2001-11-02 2012-07-23 Giuliani Int Ltd Inibidores smad7 para o tratamento de doenças do snc
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20090275496A1 (en) * 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
CA2617583A1 (en) * 2005-08-02 2007-02-08 Centenary Institute Of Cancer Medicine And Cell Biology Method for identifying regulatory t cells
JP2009529659A (ja) * 2006-03-10 2009-08-20 マウント シナイ ホスピタル 栄養膜細胞の細胞死、分化、浸潤、および／または細胞融合および代謝回転に関連する状態の診断用組成物および治療方法
EP2167647A2 (en) * 2007-06-13 2010-03-31 La Jolla Institute For Allergy And Immunology Regulatory t cells and methods of making and using same
WO2009107785A1 (ja) * 2008-02-28 2009-09-03 シスメックス株式会社 Il-17産生ヘルパーt細胞検出用マーカー及びil-17産生ヘルパーt細胞の検出方法
JP2010051307A (ja) 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
US10081809B2 (en) 2012-04-18 2018-09-25 University Of Miami Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2674147C2 (ru) 2013-03-15 2018-12-05 Ногра Фарма Лимитед Способы лечения колоректального рака
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
US20170233736A1 (en) 2014-10-17 2017-08-17 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Similar Documents

Publication Publication Date Title
JP2014531584A5 (https=)
RU2014114838A (ru) Способы контроля восприимчивости анти-smad7 терапии
JP6941324B2 (ja) 新規な肝硬変または肝線維症のマーカー
Singh et al. First mass screening of the human population to estimate the bio-load of Mycobacterium avium sub-species paratuberculosis in North India
JP7008739B2 (ja) 細胞媒介免疫応答アッセイ
CN111778341B (zh) 一种活动性肺结核的生物标志物及其应用
Singh et al. Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells
Golby et al. MicroRNA expression profiling of PPD-B stimulated PBMC from M. bovis-challenged unvaccinated and BCG vaccinated cattle
CN112608995B (zh) 一种肺结核病特异性标志物及应用和试剂盒
Masala et al. Role of Chlamydophila abortus in ovine and caprine abortion in Sardinia, Italy
Hewitt et al. A prime-boost concept using a T-cell epitope-driven DNA vaccine followed by a whole virus vaccine effectively protected pigs in the pandemic H1N1 pig challenge model
CN118979104A (zh) 脓毒症相关疾病早期诊断标志物及其用途
CN108845129A (zh) 一种活动性结核类疾病的生物标志物的应用
Hao et al. Hepatitis B virus upregulates the expression of C-reactive protein both in vivo and in vitro
Stepanova et al. Different immune response of pigs to Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuis infection
CN107267659B (zh) 检测trim基因和/或蛋白水平的产品的用途
CN107653308B (zh) 一组用于区分活动性结核病人与非结核性肺炎病人的引物对组合及试剂盒
Nouailles et al. Longitudinal omics in Syrian hamsters integrated with human data unravel complexity of moderate immune responses to SARS-CoV-2
CN103698531B (zh) Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途
CN106520916B (zh) lncRNA-MIR3945HG V2在菌阴肺结核诊断中的应用
CN110527721A (zh) 一种陈旧性结核病标志物及其应用
Jiménez et al. Expression of non-replicating persistence associated genes of Mycobacterium bovis in lymph nodes from skin test-reactor cattle
CN113755614A (zh) 布鲁氏菌病疫苗株与野毒株快速高灵敏鉴别诊断试剂盒及其使用方法
WO2022051816A1 (en) Methods of determining immune response
Chauhan et al. mRNA expression of chemokine genes in bovine tuberculosis infected crossbred cattle